title: [In vitro susceptibility of vaginal Candida albicans to antifungal drugs in Abidjan (Ivory Coast)].
abstract: OBJECTIVE
  The aim of this study was to evaluate in vitro susceptibility of vaginal Candida albicans to common antifungal drugs in Abidjan, Ivory Coast.
  
  
  METHODS
  From January to September 2008, 150 women with leucorrhoea were sampled for vaginal mycosis at the Pasteur Institute (Ivory Coast). Samples were analyzed by direct examination, Sabouraud-chloramphenicol and Sabouraud-chloramphenicol-actidione culture. C. albicans was identified after blastesis, chlamydosporulation and auxanogram tests. The susceptibility of this fungus to amphotericine B, 5-fluorocytosine, fluconazole, itraconazole and voriconazole was evaluated by a semi-solid medium microdilution technique: ATB(®) Fungus 3.
  
  
  RESULTS
  Among 62 yeasts strains isolated, C. albicans represented 45 cases or 72.6%. Vaginal itching (P=0.04) and urinary burning (P=0.002) was statistically correlated with vaginal candidosis. We observed a range of susceptibility of C. albicans strains to antifungals: 100% to amphotericine B (CMI90=0.5μg/mL); 98% to 5-fluorocytosine (CMI90=4μg/mL); 86.7% to voriconazole (CMI50=0.06μg/mL) and 80% to fluconazole (CMI50=2μg/mL and CMI90=32μg/mL). However, only 46.7% of C. albicans strains were sensitive to itraconazole (CMI50=0.125μg/mL).
  
  
  CONCLUSIONS
  These results show that vaginal C. albicans remain sensitive to the most commonly antifungal drugs used in Abidjan. However, this susceptibility should be regularly monitored.
authors.affiliation: UFR des sciences pharmaceutiques et biologiques, département de parasitologie-mycologie, université de Cocody (Abidjan), BPV 34, Abidjan, Côte d'Ivoire. vincentdjohan1@yahoo.fr
authors.forename: V
authors.initials: V
authors.lastname: Djohan
authors.forename: K E
authors.initials: KE
authors.lastname: Angora
authors.forename: A H
authors.initials: AH
authors.lastname: Vanga-Bosson
authors.forename: A
authors.initials: A
authors.lastname: Konaté
authors.forename: F K
authors.initials: FK
authors.lastname: Kassi
authors.forename: W
authors.initials: W
authors.lastname: Yavo
authors.forename: P C
authors.initials: PC
authors.lastname: Kiki-Barro
authors.forename: H
authors.initials: H
authors.lastname: Menan
authors.forename: M
authors.initials: M
authors.lastname: Koné
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000302:isolation & purification; D002176:Candida albicans / Q000187:drug effects* / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000150:complications / Q000453:epidemiology / Q000382:microbiology*; D015169:Colony Count, Microbial; D007560:Cote d'Ivoire / Q000453:epidemiology; D025141:Drug Resistance, Fungal; D005260:Female; D006801:Humans; D007973:Leukorrhea / Q000209:etiology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D014230:Triazoles / Q000494:pharmacology; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B